2021
#fff
Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisrian in Patients with hATTR PN
1
https://investors.alnylam.com/press-release?id=25366
Off
You are now leaving Alnylam.com
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Proceed to SiteYou are now leaving Alnylam.com
You will be directed to another Alnylam website that may contain information about specific treatment(s), news and more.
Proceed to Site
You will be redirected to an external site that may include social media, event registration, or other third-party content related to Alnylam.
Please note that these external sites have their own terms of service and privacy policies, which may differ from those of Alnylam.
Proceed to Site